logo
Plus   Neg
Share
Email

Stock Alert: Will RedHill Biopharma Touch A New High

Shares of RedHill Biopharma Ltd.(RDHL) more than doubled from its 52-week low of $3.26, hit last month.

All pharma companies who are either developing drugs for the new coronavirus or those who are testing their already approved drug for the treatmnet, are seeing their shares moving higher on hopes of achieving the desired results.

Most recently, this Tuesday, RDHL touched its 52-week high of $9.12 on the news of its pipeline drug, opaganib showing clinical improvement in patients with SARS-CoV-2 coronavirus infection.

Preliminary data were positive in all the six patients suffering from moderate-to-severe acute respiratory symptoms related to SARS-CoV-2 infection. They were treated with opaganib in a 14 day comppassionate-use program.

The company has submitted an investigational New Drug Application (NDA) to the FDA to evaluate the safety and efficacy of opaganib in a randomized, double-blind, placebo-controlled Phase IIA study in patients hospitalized with positive SARS-CoV-2 and pneumonia in the U.S.

Clinical studies are also being planned in Israel and Italy.

On April 28, RedHill said its H.pylori drug Talicia has been added to Prime Therapeutics NetResults national formulary.

Wednesday, RDHL was up $0.27 or 3.52% before closing at $7.93.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients. The U.S. federal government's General Services Administration or GSA has awarded a five-year federal transportation contract, estimated to be worth up to $810 million, to Uber Technologies Inc. and Lyft Inc., according to multiple reports. Under the contract, the ride-hailing companies would provide services to various public agencies and their around 4 million employees across the nation.
Follow RTT